Filing Overview
Registrant: Tivic Health Systems, Inc. (NASDAQ: TIVC). The request metadata identifies Valion Bio, Inc., but the filing names Tivic Health Systems, Inc. as the registrant.
Form 8-K date: December 7, 2022, filed December 9, 2022. The filing reports the termination of a material definitive agreement; it does not provide a financial reporting period or operating results.
Material Transaction Update
On October 7, 2022, Tivic and its wholly owned subsidiary, RB Buyer Co, LLC, entered into an Asset Purchase Agreement to acquire Reliefband Technologies, LLC from Reliefband, its beneficial owners, and related parties.
On December 7, 2022, Tivic and Reliefband mutually agreed under Section 7.1(a) of the Purchase Agreement to terminate the agreement immediately and abandon the proposed transaction.
The filing does not disclose the purchase price, termination fees, break-up costs, or other financial consequences of the termination.
Financial Metrics and Liquidity
- Revenue, profit, cash flow, margins, debt, cash balances, liquidity, and other financial metrics are not reported in this filing.
- The filing does not provide updated guidance or quantified changes to expected financial results.
Management Commentary, Outlook, and Risks
The company issued a press release dated December 9, 2022, furnished as Exhibit 99.1, announcing the termination. The text provided does not include the press release’s substantive commentary or reasons for termination.
The filing includes customary forward-looking statement warnings. Actual results may differ materially because of known and unknown risks and uncertainties, including risks described in the company’s other SEC filings.
Investor Verification Items
- Verify the correct issuer: the filing is for Tivic Health Systems, Inc., not Valion Bio, Inc.
- Review Exhibit 99.1 for the company’s stated rationale and any additional details regarding the abandoned Reliefband transaction.
- Determine from subsequent filings whether the termination resulted in fees, expenses, impairments, or changes to acquisition strategy.
- Review subsequent periodic reports for updated liquidity, financing needs, and operating guidance.